Introduction
Introduction

Adenocarcinoma (ADC) arising in Barrett's oesophagus (BO) represents the most common oesophageal cancer. Its incidence has dramatically and rapidly increased compared to other malignancies, in both the United States
and other western countries [3] . About 60% of newly diagnosed oesophageal cancers are ADC. [4] and represents the major risk factor for the development of cancer. Oesophageal ADC is a highly aggressive neoplasia with disappointingly low survival rates. At the time of diagnosis, more than 50% of patients display metastatic or unresectable disease. Moreover, a high risk for recurrent disease is present after oesophagectomy or radical chemoradiotherapy. Thus, early detection and complete surgical resection represent the only strategy to cure oesophageal cancer [2] .
BO is the only known histologic precursor of oesophageal ADC
Identification of neoplastic precursor lesions is, therefore, the mainstay of most surveillance and preventive programs. [5] [6] [7] . However, the heterogeneous behaviour of dysplasia must be taken into account; in fact, some cases progress to ADC [8] , whereas others regress or remain stable for long periods of time after anti-reflux surgery [9] . For [11, 12] . More recently, a retrospective longitudinal study of epigenetic biomarkers, including methylation of p16, RUNX3 and HPP1, has been reported [13] .
The role of the Her2/neu oncogene as a prognostic and predictive factor has been extensively investigated in several human neoplasms [14] [15] .
Recently, it has been reported that Her2 overexpression/amplification is present in dysplasia of BO [16] . This prompted us to investigate the value of Her2 overexpression/ amplification in the Barrett's dysplasia-carcinoma sequence (conversion from precursor lesion to ADC in this condition). [17, 18] . Four biopsies were performed on each centimetre of BO and where visible lesions were present, following standardized instructions for the correct orientation of the biopsies on the filter paper for histopathological assessment, to avoid tissue sampling errors [17] . Endoscopic mucosectomies were carried out according to previously described methods [19, 20] when dysplasia was documented on BO visible lesions, according to commonly accepted criteria [21] .
Patients and methods
Patient selection, clinical and endoscopic evaluation
The [22] , as previously reported [23, 24] Following these accepted criteria [28, 29] 
Results
Patient population
Immunohistochemical and FISH analysis of Her2 expression
Overall, a 100% positive correlation was found between Her2 gene amplification and protein overexpression score 3ϩ. Her2 was overexpressed/amplified in 8 of 21 (38%) cases, whereas CEP17 probe identified an aneusomy in 4 of 21 (19%). Her2 was never found amplified/overexpressed in BO alone. Its amplification/overexpression always characterized dysplasia (both LGD and HGD) and ADC (Figs 1 and 2). Her2 resulted amplified in 7 of 11 patients whose initial dysplastic lesion progressed toward a higher grade and in 1 of 10 patients who did not progress. One out of 11 patients who progressed (patients #1) was negative at the baseline (where it was diagnosed as BO), but after 10 years (120 months,
Analysis of prognostic factors
Fig. 1 Normal oesophagus (A) and Barrett's oesophagus (B) display a normal pattern of HER-2/neu protooncogene (red spots) and chromosome 17 probe (green spots). On the other hand, in LGD (C) and in HGD (D) the HER-2/neu gene is amplified (amplification if the ratio between HER-2/neu signals and CEP17 signals is Ͼ2) (original magnification, ϫ40).
Fig. 2 Area of metaplasia (Barrett's oesophagus) and dysplasia stained for HER-2 by immunohistochemistry. It is possible to recognize the different expression of HER-2: completely negative in BO and overexpressed in the areas of dysplasia. Original magnification, ϫ40).
Discussion
The [30, 31] , even though data from our country suggest that the TTP for the Italian population may be shorter with respect to other populations [7] .
Because [36] and chromosome 17 copy number increases through cancer progression [20] . However, even though in our study chromosome 17 The clinical significance of Her2 both as a prognostic factor and as a therapeutic molecular target is well-recognized in breast cancer [39, 40] . However, only a few reports exist concerning its role in precursor conditions, including bronchial, cervical and vulvar dysplasia [15, 41, 42] . In these reports, Her2 alterations were not found to be the major pathogenetic hallmark of the condition, but were related to higher proliferation index and contributed to a more malignant phenotype. This is the first report describing a potential critical role for Her2 in the pathogenesis of oesophageal carcinoma. Although this study reports on a small series and validation is required on a larger analysis, we feel that several points merit attention: (1) Her2 is associated with distinct stages of dysplasia arising in BO; (2) Her2 is associated with the progression of dysplasia and shows a trend toward a shorter TTP.
As other studies (evaluating the role of Her2 in brush cytology from BO patients) are appearing in literature, and are also consistent with our results [43, 44] , this should prompt further research into Her2 role in the pathogenesis of oesophageal ADC, to establish whether this is a potential biomarker with prognostic significance and a putative candidate for targeted chemoprevention [45] .
